Sonoma Pharmaceuticals (NASDAQ:SNOA) Share Price Passes Above 200 Day Moving Average – Should You Sell?

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA)’s stock price passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $1.78 and traded as high as $2.60. Sonoma Pharmaceuticals shares last traded at $2.55, with a volume of 19,093 shares traded.

Sonoma Pharmaceuticals Price Performance

The firm’s fifty day moving average price is $2.81 and its 200-day moving average price is $1.80. The firm has a market capitalization of $3.52 million, a P/E ratio of -0.53 and a beta of 1.43.

Institutional Trading of Sonoma Pharmaceuticals

A hedge fund recently bought a new stake in Sonoma Pharmaceuticals stock. Ground Swell Capital LLC bought a new position in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 10,400 shares of the company’s stock, valued at approximately $32,000. Ground Swell Capital LLC owned approximately 1.08% of Sonoma Pharmaceuticals at the end of the most recent reporting period. Institutional investors and hedge funds own 1.95% of the company’s stock.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.